This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RSLS ReShape Lifesciences (RSLS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ReShape Lifesciences Stock (NASDAQ:RSLS) Get ReShape Lifesciences alerts:Sign Up Key Stats Today's Range$2.80▼$4.6550-Day Range$3.16▼$15.6852-Week Range$7.48▼$56.38Volume13.69 million shsAverage Volume716,441 shsMarket Capitalization$8.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ReShape Lifesciences, headquartered in San Clemente, California, is a medical device company specializing in minimally invasive and non‐surgical therapies for obesity management and body contouring. The company’s core product portfolio includes endoscopic intragastric balloon systems that support physician‐led weight‐loss programs and non‐surgical cryolipolysis‐based devices for targeted adipose reduction without surgery. Under its ReShape Interventions division, the company markets a dual intragastric balloon system engineered to occupy gastric space, promote early satiety and aid comprehensive diet and lifestyle regimens. Through its OSPREY Medical division, ReShape provides non‐invasive body‐contouring platforms that harness controlled cooling and compression to reduce subcutaneous fat in outpatient aesthetic settings. Founded in 2010, ReShape Lifesciences has expanded beyond the United States to serve outpatient clinics and healthcare professionals in select European markets. The company partners with gastroenterologists, bariatric specialists and aesthetic practitioners to integrate its device technologies into multidisciplinary care pathways for patients seeking weight management and body‐shaping solutions. ReShape Lifesciences is guided by a leadership team with extensive expertise in medical device research, clinical development and regulatory compliance. The company continues to invest in product innovation and clinical studies aimed at enhancing the safety and efficacy of its minimally invasive and non‐invasive therapies in the growing obesity and aesthetic care markets.AI Generated. May Contain Errors. Read More Receive RSLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RSLS Stock News HeadlinesBiomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences InnovationNovember 5, 2025 | globenewswire.comReshape Lifesciences Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 20 at 1:00 AM | Porter & Company (Ad)ReShape Lifesciences Inc trading halted, news pendingAugust 15, 2025 | msn.comVyome closes Merger Transaction, Will Trade on Nasdaq as HIND TomorrowAugust 14, 2025 | finance.yahoo.com3 Penny Stocks to Watch Now, 8/14/25August 14, 2025 | msn.comVyome Therapeutics Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HINDAugust 14, 2025 | finanznachrichten.deVyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HINDAugust 13, 2025 | finance.yahoo.comSee More Headlines RSLS Stock Analysis - Frequently Asked Questions How were ReShape Lifesciences' earnings last quarter? ReShape Lifesciences Inc. (NASDAQ:RSLS) issued its quarterly earnings results on Wednesday, March, 18th. The medical device company reported $5.14 EPS for the quarter. The medical device company had revenue of $0.04 million for the quarter. ReShape Lifesciences had a negative trailing twelve-month return on equity of 547.65% and a negative net margin of 69.71%. When did ReShape Lifesciences' stock split? ReShape Lifesciences's stock reverse split on Monday, August 18th 2025.The 1-4 reverse split was announced on Wednesday, August 13th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. When did ReShape Lifesciences IPO? ReShape Lifesciences (RSLS) raised $75 million in an IPO on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. What other stocks do shareholders of ReShape Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that ReShape Lifesciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Digital Turbine (APPS), Nano Dimension (NNDM), CrowdStrike (CRWD) and Company Calendar Last Earnings3/18/2026Today5/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:RSLS CIK1371217 Webwww.reshapelifesciences.com Phone(949) 429-6680FaxN/AEmployees50Year Founded2002Profitability EPS (Trailing Twelve Months)($108.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.13 million Net Margins-69.71% Pretax Margin-47.82% Return on Equity-547.65% Return on Assets-79.89% Debt Debt-to-Equity RatioN/A Current Ratio1.53 Quick Ratio0.91 Sales & Book Value Annual Sales$8.01 million Price / Sales1.06 Cash FlowN/A Price / Cash FlowN/A Book Value($8.66) per share Price / Book-0.36Miscellaneous Outstanding Shares2,690,000Free Float2,386,000Market Cap$8.49 million OptionableNot Optionable Beta1.16 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:RSLS) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump is positioned. Elon lights the fuse.Bitcoin is sliding. Sentiment is collapsing. And retail investors are once again convinced the market is heade...Crypto 101 Media | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReShape Lifesciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ReShape Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
